Engineered T cells and their therapeutic applications in autoimmune diseases

Chimeric antigen receptor T cells (CAR-T cells) are engineered recombinant T cells, which were initially used to treat hematopoietic malignancies and are now widely used in the treatment of various diseases. Considering their intrinsic targeting efficiency, CAR-T cells show considerable potential in...

Descripción completa

Detalles Bibliográficos
Autores principales: Bao, Lei, Bo, Xiao-Chen, Cao, Huai-Wen, Qian, Chen, Wang, Zeng, Li, Bin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Science Press 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8920845/
https://www.ncbi.nlm.nih.gov/pubmed/35008131
http://dx.doi.org/10.24272/j.issn.2095-8137.2021.363
Descripción
Sumario:Chimeric antigen receptor T cells (CAR-T cells) are engineered recombinant T cells, which were initially used to treat hematopoietic malignancies and are now widely used in the treatment of various diseases. Considering their intrinsic targeting efficiency, CAR-T cells show considerable potential in the treatment of autoimmune diseases. Furthermore, regulatory T cells (Treg), a subset of CD4 T cells exhibiting immunosuppressive functions, have attracted increasing attention regarding CAR-Treg cell production. In this review, we report on recent developments in preclinical and clinical studies on CAR-T cells in autoimmune diseases and provide an outlook on opportunities and challenges of CAR-T application in such diseases.

Ejemplares similares